Business Daily from THE HINDU group of publications
Monday, Sep 25, 2006

Cross Currency

Group Sites

Marketing - New Products & Services
Industry & Economy - Health
New low-cost Hepatitis-B vaccine unveiled

Our Bureau

More affordable human vaccines on cards

Cheaper remedy
IIL is expected to price its Hepatitis-B vaccine at around 40 per cent lower than other Hepatitis-B vaccines currently in the market
This is expected to make it more affordable and also ensure its wider availability

Hyderabad , Sept. 24

Giving both the Indian private sector players and multinationals into production and marketing of Hepatitis-B vaccine a run for their money, the public sector player National Dairy Development Board (NDDB) has launched its low-cost recombinant DNA Hepatitis-B vaccine under the brand Elovac-B.

The vaccine is indigenously manufactured by Human Biologicals Institution (HBI) at its facility located at Gachibowli here. HBI is a division of Indian Immunologicals Ltd (IIL), which is a wholly owned subsidiary of NDDB.

More vaccines

Addressing newspersons on the eve of launching the product here, the IIL Managing Director, Mr K.V. Balasubramaniam, said the institute would also be coming out soon with more human vaccines such as measles, DPT, TT and combination vaccines. While vaccine for measles would be launched before the year-end, the DPT vaccine would hit the market before the fiscal-end. The combination vaccine is expected to be in the market during the next fiscal, he said.

Cheaper price

Mr Balasubramaniam said IIL would be pricing its Hepatitis-B vaccine around 40 per cent lower than the products of the Indian private sector manufacturers and MNCs currently in the market.

IIL would be making its products available through the vast network of over 2,000 Abhay Clinics across the country, apart from institutional channels.

"This idea is not only to help ensure availability of Hepatitis-B vaccine to the large population across the country at highly affordable prices but also to ensure greater availability of the vaccine," he said.


Further, he said Elovac-B would significantly gain from the Government's proposal to include Hepatitis-B vaccine in the Extended Programme of Immunisation (EPI), which is expected shortly.

IIL has a manufacturing capacity of 200-million doses of Elovac-B at the facility set up around Rs 50 crore.

He said that Elovac-B offers purity exceeding specifications provided by the regulatory authorities, and hence ensures best protection.

More Stories on : New Products & Services | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
`Analytics is the secret behind success stories'

KTM-'06 to begin on Sept 28
Hindu-Eenadu Lifestyle Show from Sept 28
Silk route
BSNL unveils scheme for Calcutta prepaid users
NTPC eyes direct sales to bulk users
Mobile Magic to launch four showrooms in Pune
AC Nielson, PDM to track star power
New low-cost Hepatitis-B vaccine unveiled

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line